Ependymoma: Evaluation and Management Updates
暂无分享,去创建一个
[1] T. Merchant,et al. Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. , 2018, International journal of radiation oncology, biology, physics.
[2] J. Jaremko,et al. Value and Limitations of Diffusion-Weighted Imaging in Grading and Diagnosis of Pediatric Posterior Fossa Tumors , 2010, American Journal of Neuroradiology.
[3] Martin Sill,et al. Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.
[4] G. Reifenberger,et al. EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.
[5] T. Zhou,et al. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Scheithauer,et al. Chemotherapy for Advanced CNS Ependymoma , 2004, Journal of Neuro-Oncology.
[7] S. Khatua,et al. Progression‐free survival of children with localized ependymoma treated with intensity‐modulated radiation therapy or proton‐beam radiation therapy , 2017, Cancer.
[8] C. Hawkins,et al. Survival benefit for pediatric patients with recurrent ependymoma treated with reirradiation. , 2012, International journal of radiation oncology, biology, physics.
[9] K. Aldape,et al. cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors , 2020, Brain pathology.
[10] Ryan A. Grant,et al. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database , 2016, Journal of Neuro-Oncology.
[11] T. Merchant,et al. Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.
[12] R. Beroukhim,et al. Myxopapillary ependymomas in children: imaging, treatment and outcomes , 2015, Journal of Neuro-Oncology.
[13] Charmaine D. Wilson,et al. A prognostic gene expression signature in infratentorial ependymoma , 2012, Acta Neuropathologica.
[14] A. Brandes,et al. A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro‐Oncologia , 2005, Cancer.
[15] M. Iqbal,et al. An overview of the management of adult ependymomas with emphasis on relapsed disease. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[16] N. Tarbell,et al. Proton Therapy for Pediatric Ependymoma: Mature Results from a Bicentric Study. , 2021, International journal of radiation oncology, biology, physics.
[17] T. Pietsch,et al. Pediatric ependymoma: an overview of a complex disease , 2021, Child's Nervous System.
[18] Jun Yang,et al. Clinical characteristics and surgical outcomes of spinal myxopapillary ependymomas , 2019, Neurosurgical Review.
[19] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[20] D. Nam,et al. Postoperative radiotherapy for WHO grade II-III intracranial ependymoma in adults: An intergroup collaborative study (KROG 18-06/KNOG 18-01). , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[21] N. Tarbell,et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] J. Montes,et al. Adjuvant radiotherapy in the treatment of pediatric myxopapillary ependymomas , 2010, Pediatric blood & cancer.
[23] M. Preusser,et al. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. , 2015, Neuro-oncology.
[24] O. Chinot,et al. Multicentric French study on adult intracranial ependymomas: prognostic factors analysis and therapeutic considerations from a cohort of 152 patients. , 2007, Brain : a journal of neurology.
[25] J. Grill,et al. High dose chemotherapy for childhood ependymona. , 1998, Journal of neuro-oncology.
[26] D. de Ruysscher,et al. Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers. , 2016, International journal of radiation oncology, biology, physics.
[27] P. Navarria,et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. , 2004, International journal of radiation oncology, biology, physics.
[28] K. Aldape,et al. High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma , 2020, Acta Neuropathologica Communications.
[29] E. Bouffet,et al. Chemotherapy for intracranial ependymomas , 1999, Child's Nervous System.
[30] Grant W. Mallory,et al. Outcomes following myxopapillary ependymoma resection: the importance of capsule integrity. , 2015, Neurosurgical focus.
[31] Haifeng Chen,et al. Risk factors for the recurrence of world health organization grade Ⅱ ependymomas of spinal cord in adults after microsurgical resections: A retrospective study of 118 patients in a single center , 2020, Clinical Neurology and Neurosurgery.
[32] Dianqing Wu,et al. Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors. , 2020, Cancer cell.
[33] S. Lam,et al. Predictors of survival in patients with spinal ependymoma , 2015, Neurological research.
[34] Mariella G. Filbin,et al. Targeting fibroblast growth factor receptors to combat aggressive ependymoma , 2021, Acta Neuropathologica.
[35] S. Zacharoulis,et al. Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study , 2016, Journal of Neuro-Oncology.
[36] D. Neuberg,et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer , 2013, Pediatric blood & cancer.
[37] R. McLendon,et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. , 2021, Neuro-oncology.
[38] C. Ames,et al. Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. , 2013, Journal of neurosurgery. Spine.
[39] D. Frappaz,et al. Intracranial ependymomas in children: society of pediatric oncology experience with postoperative hyperfractionated local radiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[40] G. Tomei,et al. Combined treatment of fourth ventricle ependymomas: report of 26 cases. , 2000, Surgical neurology.
[41] S. Pfister,et al. Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up , 2020, Neuro-Oncology.
[42] A. Brandes,et al. A multicenter study of the prognosis and treatment of adult brain ependymal tumors , 2004, Cancer.
[43] C. Sommer,et al. Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features , 2018, Brain pathology.
[44] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[45] D. Indelicato,et al. Surveillance imaging in pediatric ependymoma , 2020, Pediatric blood & cancer.
[46] M. Snuderl,et al. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival , 2017, Journal of Neuro-Oncology.
[47] R. Soffietti,et al. Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study. , 2016, Neuro-oncology.
[48] D. Frappaz,et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] M. Ivan,et al. Adjuvant radiotherapy delays recurrence following subtotal resection of spinal cord ependymomas. , 2013, Neuro-oncology.
[50] L. Kun,et al. Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[51] S. Sheth,et al. Treatment trends and overall survival in patients with grade II/III ependymoma: The role of tumor grade and location , 2020, Clinical Neurology and Neurosurgery.
[52] M. Milano,et al. Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes , 2016, Journal of Neuro-Oncology.
[53] M. Paglierani,et al. O6- Methylguanine-DNA-Methyltransferase in Recurring Anaplastic Ependymomas: PCR and Immunohistochemistry , 2008, Journal of chemotherapy.
[54] P. Ferroli,et al. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. , 2016, Neuro-oncology.
[55] Y. Shibamoto,et al. Postoperative Radiotherapy for Intracranial Ependymoma: Analysis of Prognostic Factors and Patterns of Failure , 2002, Journal of Neuro-Oncology.
[56] T. Merchant,et al. Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma , 2011, Journal of Neuro-Oncology.
[57] M. Gilbert,et al. Biology and management of ependymomas. , 2016, Neuro-oncology.
[58] J. Villano,et al. Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. , 2010, Journal of neurosurgery. Spine.
[59] Richard G Grundy,et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. , 2007, The Lancet. Oncology.
[60] Kristin L. Sainani,et al. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. , 2009, Journal of neurosurgery.
[61] S. Khatua,et al. Current therapy and the evolving molecular landscape of paediatric ependymoma. , 2017, European journal of cancer.
[62] D. Frappaz,et al. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis , 2010, Child's Nervous System.
[63] S. Terezakis,et al. Clinical Investigation : Pediatric Cancer Management of Pediatric Myxopapillary Ependymoma : The Role of Adjuvant Radiation , 2013 .
[64] M. Chamberlain,et al. Temozolomide for recurrent intracranial supratentorial platinum‐refractory ependymoma , 2009, Cancer.
[65] R. Gilbertson,et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] S. Schild,et al. In regard to the radiotherapy of myxopapillary ependymomas. , 2002, International journal of radiation oncology, biology, physics.
[67] F. Tensaouti,et al. Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[68] Clinical characteristics and long-term surgical outcome of spinal myxopapillary ependymoma: a French cohort of 101 patients , 2021, Journal of Neuro-Oncology.
[69] Gary D Bader,et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.
[70] P. Sorensen,et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma , 2020, Nature Medicine.
[71] M. Berger,et al. Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy , 2011, Journal of Neuro-Oncology.
[72] J. Finlay,et al. Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial , 2013, Journal of Neuro-Oncology.
[73] A. J. Barkovich,et al. Imaging of ependymomas: MRI and CT , 2009, Child's Nervous System.
[74] Diane D. Liu,et al. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN) , 2015, Journal of Neuro-Oncology.
[75] M. Gilbert,et al. Ependymomas of the adult: molecular biology and treatment , 2008, Current opinion in neurology.
[76] A. Wade,et al. Surveillance neuroimaging in childhood intracranial ependymoma: how effective, how often, and for how long? , 2001, Journal of neurosurgery.
[77] L. Junck,et al. Supratentorial hemispheric ependymomas: an analysis of 109 adults for survival and prognostic factors. , 2016, Journal of neurosurgery.
[78] A. Eggert,et al. Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice , 2015, Cancer Immunology, Immunotherapy.
[79] Chemotherapy for intracranial ependymoma in adults , 2016, BMC Cancer.
[80] D. Kondziolka,et al. Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. , 2010, Journal of neurosurgery. Pediatrics.
[81] T. Mikkelsen,et al. Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System , 2013, Brain pathology.
[82] N. Stence,et al. Fractionated stereotactic radiosurgery for recurrent ependymoma in children , 2013, Journal of Neuro-Oncology.
[83] S. Pfister,et al. Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study. , 2020, Neuro-oncology.
[84] T. Merchant,et al. Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.
[85] M. Berger,et al. Phase II study of pre‐irradiation chemotherapy for childhood intracranial ependymoma. Children's Cancer Group protocol 9942: A report from the Children's Oncology Group , 2012, Pediatric blood & cancer.
[86] J. Kilday,et al. Pediatric ependymomas: destined to recur? , 2021, Neuro-oncology.
[87] C. Wetmore,et al. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high‐grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021 , 2016, Cancer medicine.
[88] P. Grigsby,et al. Postoperative radiation therapy for grade II and III intracranial ependymoma. , 2005, International journal of radiation oncology, biology, physics.
[89] O. Chinot,et al. Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients. , 2010, Neuro-oncology.
[90] T. Pietsch,et al. Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified. , 2015, Neuro-oncology.
[91] P. Péran,et al. Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. , 2016, The British journal of radiology.
[92] R. Goldbrunner,et al. Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome , 2010, Acta Neurochirurgica.
[93] J. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. , 2020, Neuro-oncology.
[94] P. Brown,et al. Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis , 2013, Journal of Neuro-Oncology.
[95] T. Jaspan,et al. Assessing ‘second-look’ tumour resectability in childhood posterior fossa ependymoma—a centralised review panel and staging tool for future studies , 2016, Child's Nervous System.
[96] T. Mikkelsen,et al. AT-23A PHASE II STUDY OF LAPATINIB AND DOSE-DENSE TEMOZOLOMIDE (TMZ) FOR ADULTS WITH RECURRENT EPENDYMOMA: A CERN CLINICAL TRIAL , 2014 .
[97] I. Sardi,et al. Second-look surgery for ependymoma: the Italian experience. , 2011, Journal of neurosurgery. Pediatrics.
[98] M. Gilbert,et al. Ependymomas in Adults , 2010, Current neurology and neuroscience reports.
[99] Douglas C. Miller,et al. Ependymomas , 2013 .
[100] P. Allen,et al. Spinal myxopapillary ependymoma outcomes in patients treated with surgery and radiotherapy at M.D. Anderson Cancer Center , 2006, Journal of Neuro-Oncology.
[101] R. Stupp,et al. Bevacizumab for recurrent ependymoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] A. Raghunathan,et al. Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. , 2019, Journal of neuropathology and experimental neurology.
[103] K. Ichimura,et al. Temozolomide Treatment for Pediatric Refractory Anaplastic Ependymoma with Low MGMT Protein Expression , 2016, Pediatric blood & cancer.